Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Conference Coverage

Psoriasis
Conference Coverage
Interleukin Inhibitors for Moderate to Severe Psoriasis
04/22/2022
Coleen Stern, Senior Managing Editor
April Armstrong, MD, MPH, presented the session “The Role of Interleukin Inhibitors in the Treatment of Moderate to Severe Psoriasis.”
April Armstrong, MD, MPH, presented the session “The Role of Interleukin Inhibitors in the Treatment of Moderate to Severe Psoriasis.”
April Armstrong, MD, MPH,...
04/22/2022
The Dermatologist

Advertisement

Psoriasis
Conference Coverage
A Deep Dive Into Combination Therapy
04/22/2022
Coleen Stern, Senior Managing Editor
Joseph Merola, MD, MMSc, and Adam Cheifetz, MD, presented their discussion-based session, “Deep Dive: Combination Therapy Approaches.”
Joseph Merola, MD, MMSc, and Adam Cheifetz, MD, presented their discussion-based session, “Deep Dive: Combination Therapy Approaches.”
Joseph Merola, MD, MMSc, and...
04/22/2022
The Dermatologist
skin cancer examination
Conference Coverage
Collaborative Cases: Inflammation and Malignancies
04/22/2022
Jessica Garlewicz, Associate Digital Editor
On the 2nd day of the 9th Annual Interdisciplinary Autoimmune Summit, Joseph Merola, MD, MMSc, and Adam Cheifetz, MD, opened with their session, “Collaborative Cases in IMIDs".
On the 2nd day of the 9th Annual Interdisciplinary Autoimmune Summit, Joseph Merola, MD, MMSc, and Adam Cheifetz, MD, opened with their session, “Collaborative Cases in IMIDs".
On the 2nd day of the 9th Annual...
04/22/2022
The Dermatologist
JAK-Treatment
Conference Coverage
Best of Dermatology 2021: JAK Inhibitors
04/22/2022
Jessica Garlewicz, Associate Digital Editor
In the session, “Editors Focus - Best of 2021 Dermatology, Gastroenterology & Rheumatology” presented at IAS 2022, Joel Gelfand, MD MSCE, shared some exciting news on the use of JAKs in dermatology.
In the session, “Editors Focus - Best of 2021 Dermatology, Gastroenterology & Rheumatology” presented at IAS 2022, Joel Gelfand, MD MSCE, shared some exciting news on the use of JAKs in dermatology.
In the session, “Editors Focus -...
04/22/2022
The Dermatologist

Advertisement

pustular psoriasis
Conference Coverage
A Deep Dive Into Dual Targeting
04/21/2022
Coleen Stern, Senior Managing Editor
Stephen Hanauer, MD, FACG; Joel Gelfand, MD, MSCE; and Leonard Calabrese, DO, got together to discuss dual targeted therapy.
Stephen Hanauer, MD, FACG; Joel Gelfand, MD, MSCE; and Leonard Calabrese, DO, got together to discuss dual targeted therapy.
Stephen Hanauer, MD, FACG; Joel...
04/21/2022
The Dermatologist
Psoriasis_COVID-19_COVID
Conference Coverage
The Impact of IMID Treatment on COVID-19 Risk
04/21/2022
Riya Gandhi, MA, Associate Editor
Joel M. Gelfand, MD, MSCE, kicked off the session by saying, “In spring 2020, COVID toes were reported to occur 1 to 4 weeks post onset of COVID-19 symptoms.”
Joel M. Gelfand, MD, MSCE, kicked off the session by saying, “In spring 2020, COVID toes were reported to occur 1 to 4 weeks post onset of COVID-19 symptoms.”
Joel M. Gelfand, MD, MSCE,...
04/21/2022
The Dermatologist
severe psoriasis
Conference Coverage
Skin Disease States and Remissions
04/21/2022
Jessica Garlewicz, Associate Digital Editor
At IAS, Joseph Merola, MD, MMSc, and Adam Cheifetz, MD, presented their discussion-based session, “Deep Dive: Can We Achieve Remission?"
At IAS, Joseph Merola, MD, MMSc, and Adam Cheifetz, MD, presented their discussion-based session, “Deep Dive: Can We Achieve Remission?"
At IAS, Joseph Merola, MD, MMSc,...
04/21/2022
The Dermatologist

Advertisement

psoriasis on arm
Conference Coverage
Collaborating in IMIDs: Anti-TNFs
04/21/2022
Jessica Garlewicz, Associate Digital Editor
During the Interdisciplinary Autoimmune Summit , Joseph Merola, MD, MMSc, joined his colleague Adam Cheifetz, MD, for their session, “Collaborative Cases in IMIDs.”
During the Interdisciplinary Autoimmune Summit , Joseph Merola, MD, MMSc, joined his colleague Adam Cheifetz, MD, for their session, “Collaborative Cases in IMIDs.”
During the Interdisciplinary...
04/21/2022
The Dermatologist
Wan-Fai Ng, PhD
Conference Coverage
The Complex Network of Potential Fatigue Causes in IMIDs
04/21/2022
At the 2022 Interdisciplinary Autoimmune Summit, Dr Wan-Fai Ng presented on the issue of fatigue in immune-mediated inflammatory diseases, including the impact it has on patients, potential contributing mechanisms, and approaches for managing...
At the 2022 Interdisciplinary Autoimmune Summit, Dr Wan-Fai Ng presented on the issue of fatigue in immune-mediated inflammatory diseases, including the impact it has on patients, potential contributing mechanisms, and approaches for managing...
At the 2022 Interdisciplinary...
04/21/2022
Autoimmune
Osterholm
Conference Coverage
How COVID-19 Will Change the World
04/21/2022
Infectious disease expert Michael Osterholm, PhD, MPH, calls for rebuilding public health, fixing a broken health information system, and planning for the exception instead of the average, to better respond to pandemics.
Infectious disease expert Michael Osterholm, PhD, MPH, calls for rebuilding public health, fixing a broken health information system, and planning for the exception instead of the average, to better respond to pandemics.
Infectious disease expert...
04/21/2022
Autoimmune

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Popular Articles
Quiz
Coexisting RA and AS
04/28/2021
The coexistence of rheumatoid arthritis and ankylosing spondylitis in one patient is rare, often leading to misdiagnosis. Take our quick quiz and find out which patients present key signs at onset.
The coexistence of rheumatoid arthritis and ankylosing spondylitis in one patient is rare, often leading to misdiagnosis. Take our quick quiz and find out which patients present key signs at onset.
The coexistence of rheumatoid...
04/28/2021
Autoimmune
Conference Insights
Orofacial Granulomatosis
08/06/2018
08/06/2018
Autoimmune
New Anti-Inflammatory Drug Improves Active PsA Symptoms
11/09/2017
Previous trials demonstrated that a drug for moderate to severe plaque psoriasis remained safe and effective through 60 weeks of use. In the UNCOVER-3 study, researchers tested the safety and efficacy of this drug through 108 weeks of use.
Previous trials demonstrated that a drug for moderate to severe plaque psoriasis remained safe and effective through 60 weeks of use. In the UNCOVER-3 study, researchers tested the safety and efficacy of this drug through 108 weeks of use.
Previous trials demonstrated...
11/09/2017
Autoimmune
News
Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Can Last Months
04/08/2020
Immune checkpoint inhibitors have improved cancer outcomes but are associated with immune-related adverse events. Findings from a recent study highlighted the prevalence of and factors associated with immune checkpoint inhibitor-associated...
Immune checkpoint inhibitors have improved cancer outcomes but are associated with immune-related adverse events. Findings from a recent study highlighted the prevalence of and factors associated with immune checkpoint inhibitor-associated...
Immune checkpoint inhibitors...
04/08/2020
Autoimmune
News
Expert Recommendations for Managing Autoimmune Bullous Diseases in COVID-19 Era
05/18/2020
Experts from the United States, France, and Germany published guidance on managing patients with autoimmune bullous diseases during the COVID-19 pandemic.
Experts from the United States, France, and Germany published guidance on managing patients with autoimmune bullous diseases during the COVID-19 pandemic.
Experts from the United States,...
05/18/2020
Autoimmune

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Stay In the Know

Autoimmune Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use